Back to search
FDAFDA · Food and drugs·Recall number D-0648-2020

Ranitidine Capsules 300 mg, 30 count bottles. Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623, NDC 62559-691-30.

Published January 15, 2020 · Recall initiated: January 7, 2020

Summary

FDA records drug Class II recall D-0648-2020, published January 15, 2020 and initiated January 7, 2020. Recalling firm: Appco Pharma LLC; Status: Terminated; Reported quantity: 1,632 bottes; Lot: Batch # 1905227UE, exp. date Apr-2021 1905228UE, exp. date Apr-2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Appco Pharma LLC
Distributor
Product was distributed to 6 major distributors/wholesalers some with multiple locations who may have further distribute the product.
Lot
Batch # 1905227UE, exp. date Apr-2021 1905228UE, exp. date Apr-2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ranitidine Capsules 300 mg, 30 count bottles. Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623, NDC 62559-691-30. recalled?

Yes. FDA published recall D-0648-2020 on January 15, 2020. Reported hazard: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

What should I do if I have this product?

Voluntary: Firm initiated · Press Release